Cidara Therapeutics, Inc. (CDTX)

Market Cap	57.07M
Revenue (ttm)	63.91M
Net Income (ttm)	-22.93M
Shares Out	4.56M
EPS (ttm)	-5.20
PE Ratio	n/a
Forward PE	5.75
Dividend	n/a
Ex-Dividend Date	n/a

Volume	53,967
Open	11.75
Previous Close	12.68
Day's Range	11.75 - 13.20
52-Week Range	10.00 - 29.60
Beta	1.01
Analysts	Strong Buy
Price Target	61.67 (+392.97%)
Earnings Date	Apr 22, 2024

About CDTX

Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388,...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 15, 2015
• Employees: 69
• Stock Exchange: NASDAQ
• Ticker Symbol: CDTX

Financial Performance

In 2023, CDTX's revenue was $63.91 million, a decrease of -0.84% compared to the previous year's $64.45 million. Losses were -$22.93 million, -31.72% less than in 2022.

Analyst Forecast

According to 4 analysts, the average rating for CDTX stock is "Strong Buy." The 12-month stock price forecast is $61.67, which is an increase of 392.97% from the latest price.

Price Target

$61.67

(392.97% upside)

Analyst Consensus: Strong Buy